Delcath Systems, Inc. (DCTH)
| Previous Close | 5.21 |
| Open | 5.17 |
| Bid | 5.14 x 200 |
| Ask | 5.25 x 300 |
| Day's Range | 5.12 - 5.26 |
| 52 Week Range | 2.25 - 7.99 |
| Volume | |
| Avg. Volume | 213,438 |
| Market Cap | 132.03M |
| Beta (5Y Monthly) | 0.60 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- PR Newswire
Delcath Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Delcath Systems, Inc. (Nasdaq: DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted an equity award, previously approved by the Company's Compensation Committee, as a material inducement to the employment of one individual whose employment commenced in March 2024.
- PR Newswire
Delcath Systems Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update
Delcath Systems, Inc. (Nasdaq: DCTH) ("Delcath" or the "Company"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today reported recent business highlights and financial results for the fourth quarter and full year ended December 31, 2023.
- PR Newswire
Delcath Systems Closes $7 Million Private Placement
Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, confirmed the closing of the previously announced private placement with certain accredited investors comprised of existing investors, Delcath Executives and members of its Board of Directors, for a private placement transaction (the "Private Placement").
